Family Office
SK Capital Partners
Parramatta, NSW, Australia
Type
Family Office
Check size
n/a
Verticals
specialty materials, ingredients, life sciences
Investment thesis
SK Capital Partners is a private investment firm founded in 2007, specializing in the chemicals, materials, and pharmaceuticals sectors. Headquartered in New York City, the firm manages more than $7 billion in assets and focuses on acquiring and building businesses with strong growth potential. SK Capital Partners is known for its operational expertise and has a portfolio that includes several prominent companies in specialty chemicals and pharmaceuticals. The firm has a track record of driving transformation and value creation in its investments, with recent activity including strategic acquisitions and divestitures in its core industries.
Recent investments
- →Apotex
- →Spectrum Vascular
- →Axillon Aerospace
+ 3 more deals. Score your deck to see the full investment history.
Partners
5 partners on file at this firm, with the firm's email pattern for cold outreach.
Partner names + email patterns are part of the deck-upload bundle. Score your deck (free, 30 seconds) to unlock direct contact for this firm and 45,000+ others.
Score my deck → unlock contactsInvestment focus
Business models
services, biotech_therapeutics
Customer segments
Enterprise, Mid-market
Geography
US, Europe, APAC, LATAM
Links
Want to know if SK Capital Partners is the right fit for your deck?
Drop your pitch deck. Claude scores it on the 8 dimensions VCs evaluate and tells you which of the 45,000+ firms in our database are the best matches.
Score your deck (free, 30 seconds) →SK Capital Partners is based in Australia. Browse other active investors in the same country.
Similar investors
Seed VC
Gold Nest Capital
life sciences, healthcare, biotech
Seed VC
4BIO Capital
advanced therapies, gene therapy, life sciences
Seed VC
Gold Nest Capital
life sciences, healthcare, biotech
Seed VC
East West Capital Partners
pharmaceuticals, biotech, medical technology
Family Office
Lobnek Wealth Management
life sciences, private equity, M&A